The Food and Drug Administration has approved several generic versions of the Boehring Ingelheim’s Mobic Tablets, (Meloxicam) a popular NSAID (non-steroidal anti-inflammatory) used in the treatment of osteoarthritis and rheumatoid arthritis.

Meloxicam is an extremely popular drug, ranking 38th in dollar sales of brand-name drugs in the United States. A generic alternative will mean significant savings for patients. The approval of generic drugs can effectively aid in the lowering of health care costs and currently are used to fill more than 50% of all prescriptions written in the U.S.